Who are Zolpidem Hemitartrate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zolpidem IR, Zolpidem MR, Zolpidem CR, Zolpidem (SL800750), GSK1755165; placebo; zopiclone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zolpidem-hemitartrate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Zolpidem Hemitartrate — Competitive Intelligence Brief

Zolpidem Hemitartrate (Zolpidem Hemitartrate) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-benzodiazepine hypnotic (Z-drug). Area: Neurology / Sleep Medicine.

marketed Non-benzodiazepine hypnotic (Z-drug) GABA-A receptor (alpha-1 subunit selective) Neurology / Sleep Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Zolpidem Hemitartrate (Zolpidem Hemitartrate) — EMS. Zolpidem hemitartrate is a sedative-hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep onset.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Zolpidem Hemitartrate TARGET	Zolpidem Hemitartrate	EMS	marketed	Non-benzodiazepine hypnotic (Z-drug)	GABA-A receptor (alpha-1 subunit selective)
Zolpidem IR	Zolpidem IR	Astellas Pharma Inc	marketed	Non-benzodiazepine hypnotic (Z-drug)	GABA-A receptor (alpha-1 subunit selective)
Zolpidem MR	Zolpidem MR	Astellas Pharma Inc	marketed	Non-benzodiazepine hypnotic (Z-drug)	GABA-A receptor (alpha-1 subunit selective)
Zolpidem CR	Zolpidem CR	Henry Ford Health System	marketed	Non-benzodiazepine hypnotic (Z-drug)	GABA-A receptor (alpha-1 subunit selective)
Zolpidem (SL800750)	Zolpidem (SL800750)	Sanofi	marketed	Non-benzodiazepine hypnotic (Z-drug)	GABA-A receptor (alpha-1 subunit selective)
GSK1755165; placebo; zopiclone	GSK1755165; placebo; zopiclone	GlaxoSmithKline	phase 3	Non-benzodiazepine hypnotic (Z-drug)	GABA-A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-benzodiazepine hypnotic (Z-drug) class)

Astellas Pharma Inc · 2 drugs in this class
EMS · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Henry Ford Health System · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zolpidem Hemitartrate — Competitive Intelligence Brief. https://druglandscape.com/ci/zolpidem-hemitartrate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab